CD274 and head and neck squamous cell carcinoma: Part 2 aimed to estimate overall survival (OS) in patients with PD-1-/PD-L1-experienced relapsed/refractory (RR) HNSCC treated with study intervention compared to those treated with investigator’s choice of standard of care (SOC).